Summit Therapeutics (SMMT)
(Delayed Data from NSDQ)
$24.54 USD
-1.68 (-6.41%)
Updated Sep 18, 2024 03:59 PM ET
After-Market: $24.54 0.00 (0.00%) 4:44 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
SMMT 24.54 -1.68(-6.41%)
Will SMMT be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for SMMT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SMMT
Instil Bio Stock Skyrockets 641% in One Week: Here's Why
Biotech Stock Roundup: TERN, SMMT Stocks Surge on Study Data, GSK's Vaccine Study Fails & More
SMMT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Summit Hits Record High on Lung Cancer Drug Topping Merck's Keytruda
MRK Stock Dips After SMMT's Cancer Drug Outshines Keytruda in Study
Company News for Sep 10, 2024
Other News for SMMT
Largest borrow rate increases among liquid names
BioNTech price target raised to $131 from $97 at UBS
BioNTech raised to buy at Jefferies on new cancer drug
Shopify upgraded, SolarEdge downgraded: Wall Street's top analyst calls
Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study